trial updates in mrcc from asco: keynote-427, resort, e2810 & immotion151
Published 6 years ago • 151 plays • Length 4:20Download video MP4
Download video MP3
Similar videos
-
4:10
non-clear cell kidney cancer trial updates: calypso and keynote-427
-
4:56
dr. rini discusses asco 2023 data in frontline rcc: clear and keynote-426 trials
-
1:33
dr. powles on the results of the keynote-426 trial in mrcc
-
2:06
updated analysis of keynote-426: pembro plus axitinib vs sunitinib in mrcc
-
2:46
keynote-427 updates: first-line pembrolizumab monotherapy in patients with advanced clear cell r...
-
7:43
perioperative myocardial infarction
-
5:10
real-world treatment outcomes of 1l axitinib pembrolizumab in patients with advanced rcc in the us
-
9:59
know your options endoscopic mucosal resection emr
-
4:23
first-line therapy options for rcc: lessons from checkmate 214 and keynote-427
-
3:03
adjuvant pembrolizumab improves rcc disease-free survival | toni choueiri
-
1:08
clinical trials in adjuvant rcc
-
7:02
trial updates from asco gi 2021
-
2:04
keynote-b61: extended follow-up analysis
-
0:58
michael atkins, md, regarding the keynote 426 phase iii trial in metastatic renal cell carcinoma
-
3:10
keynote-426 rationale and results: pembro plus axitinib vs. sunitinib in mrcc
-
3:28
dr rini on a biomarker analysis for pembrolizumab/axitinib in advanced rcc
-
1:58
dr. rischin on keynote-048 results in head and neck squamous cell carcinoma
-
4:52
asco gi 2021: trial updates
-
2:23
trial updates at asco gi 2021
-
1:00
pembrolizumab/axitinib and avelumab/axitinib combo for rcc
-
1:01
asco gu23 toni choueiri, md: keynote-564 subgroup analysis | dana-farber cancer institute